Literature DB >> 12576957

Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome.

Eric R Pacht1, Stephen J DeMichele, Jeffrey L Nelson, Judy Hart, Ann K Wennberg, James E Gadek.   

Abstract

OBJECTIVE: Previously, we showed that acute respiratory distress syndrome patients fed an enteral diet containing eicosapentaenoic acid and gamma-linolenic acid and elevated antioxidants (EPA+GLA; Oxepa) had significantly reduced pulmonary inflammation, increased oxygenation, and improved clinical outcomes. In a subset of acute respiratory distress syndrome patients from this trial, we performed a preliminary examination of the potential mechanisms underlying these clinical improvements by retrospectively testing the hypothesis that enteral feeding with EPA+GLA could reduce alveolar-capillary membrane protein permeability and the production of interleukin (IL)-8, IL-6, tumor necrosis factor-alpha, and leukotriene B4 that are responsible, in part, for pulmonary inflammation.
DESIGN: Prospective, randomized, double-blind, controlled clinical trial.
SETTING: Intensive Care Unit of the Ohio State University Medical Center. PATIENTS: A total of 67 patients were enrolled who met defined criteria for acute lung injury/acute respiratory distress syndrome.
INTERVENTIONS: A total of 43 of 67 evaluable patients randomly received either EPA+GLA or an isonitrogenous, isocaloric standard diet that was tube fed at a minimum caloric delivery of 75% of basal energy expenditure times 1.33 for at least 4 to 7 days.
MEASUREMENTS AND MAIN RESULTS: Bronchoalveolar lavage (BAL) was performed at baseline and study days 4 and 7 to obtain BAL fluid (BALF) for measurement of total protein, ceruloplasmin, and transferrin, total neutrophil count, IL-8, IL-6, tumor necrosis factor-alpha, and leukotriene B4. Oxygenation, measured as Pao2/Fio2, was assessed before BAL. Patients fed EPA+GLA had a significant reduction in BALF ceruloplasmin and IL-8 during the study as compared with patients fed the control diet. BALF levels of total protein, neutrophils, and leukotriene B4 tended to decrease in EPA+GLA patients over the course of the study as compared with control patients. BALF levels of IL-6 declined similarly during the study in both groups. A trend toward a reduction in BALF tumor necrosis factor-alpha was observed on study day 7 in the EPA+GLA group as compared with control patients. Significant improvements in oxygenation (Pao2/Fio2) occurred in EPA+GLA patients on study day 4 as compared with controls. Correlation analysis revealed significant relationships between BALF neutrophil counts and indices of alveolar-capillary membrane protein permeability, IL-8, and leukotriene B4.
CONCLUSIONS: This preliminary investigation showing a decrease in BALF levels of IL-8 and leukotriene B4 and the associated reduction of BALF neutrophils and alveolar membrane protein permeability in acute respiratory distress syndrome patients fed EPA+GLA support, in part, the potential mechanisms underlying the previously described clinical improvements with this diet. Additional controlled studies are needed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576957     DOI: 10.1097/01.CCM.0000049952.96496.3E

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  42 in total

Review 1.  Fish oil in critical illness: mechanisms and clinical applications.

Authors:  Renee D Stapleton; Julie M Martin; Konstantin Mayer
Journal:  Crit Care Clin       Date:  2010-07       Impact factor: 3.598

Review 2.  Immune-modulating enteral formulations: optimum components, appropriate patients, and controversial use of arginine in sepsis.

Authors:  Minhao Zhou; Robert G Martindale
Journal:  Curr Gastroenterol Rep       Date:  2007-08

3.  Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care VIII--Nutritional support of the trauma patient.

Authors:  Grant E O'Keefe; Marilyn Shelton; Joseph Cuschieri; Ernest E Moore; Stephen F Lowry; Brain G Harbrecht; Ronald V Maier
Journal:  J Trauma       Date:  2008-12

4.  Nutritional therapy for cancer cachexia.

Authors:  R F Grimble
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

5.  Fish oil-supplemented parenteral nutrition in severe acute pancreatitis patients and effects on immune function and infectious risk: a randomized controlled trial.

Authors:  Xinying Wang; Weiqin Li; Feng Zhang; Liya Pan; Ning Li; Jieshou Li
Journal:  Inflammation       Date:  2009-10       Impact factor: 4.092

6.  Bronchoalveolar fluid and plasma inflammatory biomarkers in contemporary ARDS patients.

Authors:  Renee D Stapleton; Benjamin T Suratt; Margaret J Neff; Mark M Wurfel; Lorraine B Ware; John T Ruzinski; Ellen Caldwell; Teal S Hallstrand; Polly E Parsons
Journal:  Biomarkers       Date:  2019-03-04       Impact factor: 2.658

Review 7.  Enteral omega-3 fatty acid supplementation in adult patients with acute respiratory distress syndrome: a systematic review of randomized controlled trials with meta-analysis and trial sequential analysis.

Authors:  Daojun Zhu; Yi Zhang; Shuo Li; Lu Gan; Huaizhi Feng; Wei Nie
Journal:  Intensive Care Med       Date:  2014-02-21       Impact factor: 17.440

8.  The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury.

Authors:  Hiroyuki Seki; Koichi Fukunaga; Makoto Arita; Hiroyuki Arai; Hiroki Nakanishi; Ryo Taguchi; Taku Miyasho; Rina Takamiya; Koichiro Asano; Akitoshi Ishizaka; Junzo Takeda; Bruce D Levy
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

Review 9.  Alcohol abuse and pulmonary disease.

Authors:  Darren M Boé; R William Vandivier; Ellen L Burnham; Marc Moss
Journal:  J Leukoc Biol       Date:  2009-07-14       Impact factor: 4.962

10.  A novel effect of eicosapentaenoic acid: improved diaphragm strength in endotoxemia.

Authors:  Philip C Calder
Journal:  Crit Care       Date:  2010-04-23       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.